

The R&D pipeline

19 projects in development,
13 in Phase 2 or beyond.

- VYVANSE non-ADHD—Phase 2 clinical trials actively enrolling patients with data beginning 2011.
- LIALDA—global Phase 3 in diverticulitis ongoing.
- VPRIV—responded to evolving market demands in 2009, planning for launch in 2010.
- Hunter Syndrome Central Nervous System ('CNS')—the first of a new platform of direct delivery of proteins to the CNS. Advancement into the clinic in 2010, first patient dosed.

Indication	Project	Phase	Estimated submission	Estimated launch
SPECIALTY PHARMA				
ADHD—adolescent	DAYTRANA (US)	Registration		2010
ADHD	VYVANSE (EU)	3	2011	2012
ADHD—for use in combination with other ADHD treatments	INTUNIV (US)	3	2010	2011
Ulcerative colitis—maintenance of remission treatment	LIALDA (US)	3	2010	2011
Diverticulitis	LIALDA/MEZAVANT	3	2012	2013
Chronic Kidney disease	FOSRENOL (US)	Pre-registration		
Prevention and reduction of scarring	JUVISTA (EU)	3		2013–2016
Adjunctive therapy in depression	VYVANSE	2		
Cognitive impairment in depression	VYVANSE	2		
Negative symptoms and cognitive impairment in schizophrenia	VYVANSE	2		
Platelet lowering	SPD 535	1		2013–2016

HUMAN GENETIC THERAPIES				
Gaucher disease	VPRIV (EU)	Registration	H2–2009	2010
Fabry disease	REPLAGAL (US)	Registration		2010
Hereditary angioedema	FIRAZYR (US)	3		2011
Hunter syndrome CNS	HGT 2310	1/2		2013–2016
Metachromatic Leukodystrophy ('MLD')	HGT 1110	Pre-clinical		2013–2016
Sanfilippo A syndrome	HGT 1410	Pre-clinical		2013–2016
Globoid Cell Leukodystrophy ('GLD', Krabbe)	HGT 2610	Pre-clinical		2013–2016
Santaris collaboration	3 targets	Pre-clinical		2013–2016